# CONTACT-02 (NCT04446117)

> Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04446117
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Exelixis
- Conditions: Metastatic Prostate Cancer; Prostate Adenocarcinoma
- Interventions: Cabozantinib; Atezolizumab; Abiraterone Acetate; Enzalutamide; Prednisone
- Enrollment: 575
- Primary outcome: Duration of Progression Free Survival (PFS) Per Response Evaluable Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Radiology Committee (BIRC)
- Primary outcome: Duration of Overall Survival (OS)

## Commentary we found

- X threads: 86
- Podcasts: 16
- YouTube: 14
- X videos: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=contact-02-nct04446117

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04446117", "email": "<work email>"}; the inbox owner confirms by the emailed link.